Clinical studies have linked anticholinergic drugs to dementia risk. However, it remains unclear whether this is due to the direct effects of these medications or a predisposition to dementia in the participants. Angelica Ramos is investigating whether different classes of anticholinergics induce molecular phenotypes related to Alzheimer’s disease. Using human iPSC-derived neurons from study participants, she treats the cells with various anticholinergic classes and evaluates the levels of phosphorylated Tau, beta-amyloid, and cytotoxicity, along with changes in synaptic gene expressions.